Navigation Links
Jefferson is first academic medical center to offer FDA-approved BRAF mutation for melanoma patients
Date:11/8/2011

PHILADELPHIAThomas Jefferson University Hospital is the first academic medical center in the United States to offer the recently-approved U.S. Food and Drug Administration (FDA) diagnostic tool that tests melanoma patients for the BRAF mutation (which occurs in about half of all cases) and ultimately determines if they'll benefit from a new, potentially life-saving drug.

In August, the FDA approved the oral drug vemurafenib to treat patients whose melanoma cells have the BRAF V600E mutation, as determined by the companion diagnostic test, after clinical trials showed that the drug significantly extended survival in metastatic melanoma patients with the mutation.

Jefferson's clinical laboratories have officially begun utilizing the FDA-approved test to help determine melanoma patients' status and a subsequent and immediate treatment plan. According to Roche Diagnostics, its tool has improved sensitivity, accuracy and speed compared to other commonly used detection methods.

"It is very important to us at Jefferson to offer patients a personalized approach, starting with the pathology of their diseases all the way through their treatment," says Stephen C. Peiper, M.D., Peter A. Herbut Professor and Chair of the Department of Pathology, Anatomy and Cell Biology at Thomas Jefferson University.

"Melanoma is a deadly skin cancer, and this FDA-approved diagnostic tool plays a pivotal role in our approach to it. The BRAF mutation test will allow us to quickly and accurately identify patients here at the hospital who will respond positively to this new treatment," he adds.

An estimated 50 percent of patients with melanoma have this type of mutation.

The FDA approval of vemurafenib is based on results from two clinical studies in people with BRAF V600E mutation-positive, inoperable or metastatic melanoma as determined by the mutation test.

The risk of death was reduced by 56 percent for people who received vemurafenib compared to those who received chemotherapy. People who received vemurafenib also had a 74 percent reduced risk of the disease getting worse or dying compared to those who received chemotherapy. The confirmed investigator-assessed response rate (those who experienced tumor shrinkage) in people who received vemurafenib was 48.4 percent compared to 5.5 percent for those who received chemotherapy.

Vemurafenib is a BRAF inhibitor that blocks the function of the V600E-mutated BRAF protein and should be used only in people whose inoperable or metastatic melanoma carries a mutation.


'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Thomas Jefferson University Hospital cuts Whipple procedure wound infections in half with new measures
2. Jefferson physician named an Educator of the Year by the Assocociation of Residents in Radiation Oncology
3. Thomas Jefferson University Hospital adopts new imaging agent to improve detection of bladder cancer
4. Thomas Jefferson University and hospitals tasked to find new radiation drugs
5. FDA approval of brain aneurysm device gives Jefferson neurosurgeons another life-saving tool
6. Jefferson doctors strengthen case for high-dose radiotherapy technique after radical prostatectomy
7. Kimmel Cancer Center at Jefferson breast cancer symposium features latest in research, treatment
8. Jefferson clinical trial: Can a cholesterol drug prevent colon cancer?
9. Thomas Jefferson University professor elected AAAS Fellow
10. Jefferson study determines bone marrow stromal stem cells may aid in stroke recovery
11. CancerCare names Jefferson professor Physician of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... For the ... Lawrenceville, New Jersey and the surrounding area, is inaugurating a charity event ... more commonly known as Lou Gehrig's disease or motor neurone disease, is a ...
(Date:1/19/2017)... Los Angeles, CA (PRWEB) , ... January 18, 2017 , ... ... serious hazards while driving during a rain storm by slowing down and increasing the ... published on Fox 40. Los Angeles based car accident attorney Raymond R. Hassanlou notes ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... that will simplify the editing process for all media productions," said Christina Austin ... package of 30 simplistically styled self-animating paragraphs designed for multi-lined text purposes. ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting of a ... about the benefits of fidgeting to relieve stress and anxiety. No one was ... Think Ink Pen had just completed a successful Kickstarter campaign raising $67,000 on the ...
(Date:1/18/2017)... USA; SAN JOSE, Calif, USA; and SHANGHAI, China – , ... ... (PRWEB) January 18, 2017 -- Global public health organization NSF ... arsenic V (pentavalent arsenic) to NSF/ANSI 53: Drinking Water Treatment ... water treatment units. This certification verifies that MicroCeramics’ NanoNose Pitcher ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... CLEVELAND , Jan. 18, 2017  ViewRay, ... the world,s first and only clinical MRI-guided radiation ... gross proceeds of approximately $26.1 million through a ... Puissance Capital Management led the financing and was ... OrbiMed Advisors, LLC and Kearny Venture Partners, and ...
(Date:1/19/2017)... 18, 2017 The Academy of Managed ... Administration (FDA) for its release today of draft ... decision makers can proactively share clinical and economic ... as emerging therapies awaiting FDA approval. ... that AMCP developed during two multi-stakeholder meetings last ...
(Date:1/18/2017)... 2017 Research and Markets has announced the addition ... User - Global Opportunity Analysis and Industry Forecast, 2014-2022" report to ... Vital signs ... to reach $5,491 million by 2022, growing at a CAGR of 5.8% ... was the leading regional market in global vital signs monitoring devices ...
Breaking Medicine Technology: